Reply: To PMID 24999721
- PMID: 26166802
- DOI: 10.1097/IAE.0000000000000682
Reply: To PMID 24999721
Comment on
-
Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.Retina. 2014 Dec;34(12):2439-43. doi: 10.1097/IAE.0000000000000238. Retina. 2014. PMID: 24999721
-
Correspondence.Retina. 2015 Aug;35(8):e54. doi: 10.1097/IAE.0000000000000681. Retina. 2015. PMID: 26166801 No abstract available.
Similar articles
-
Reply.Retina. 2016 Feb;36(2):e10-2. doi: 10.1097/IAE.0000000000000918. Retina. 2016. PMID: 26696314 No abstract available.
-
Correspondence.Retina. 2016 Feb;36(2):e9-e10. doi: 10.1097/IAE.0000000000000917. Retina. 2016. PMID: 26655619 No abstract available.
-
Correspondence.Retina. 2015 Aug;35(8):e54. doi: 10.1097/IAE.0000000000000681. Retina. 2015. PMID: 26166801 No abstract available.
-
Clinical Trials in Branch Retinal Vein Occlusion.Middle East Afr J Ophthalmol. 2016 Jan-Mar;23(1):38-43. doi: 10.4103/0974-9233.172294. Middle East Afr J Ophthalmol. 2016. PMID: 26957837 Free PMC article. Review.
-
[Management of aflibercept in routine clinical practice].Arch Soc Esp Oftalmol. 2015 Mar;90 Suppl 1:29-34. doi: 10.1016/S0365-6691(15)30007-1. Arch Soc Esp Oftalmol. 2015. PMID: 25925049 Review. Spanish.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources